Cheng, Ying
Wu, Chunjiao
Wu, Lin
Zhao, Jun
Zhao, Yanqiu
Chen, Lulu
Xin, Ying
Zhang, Liang
Pan, Pinhua
Li, Xingya
Li, Juan
Dong, Xiaorong
Tang, Ke
Gao, Emei
Yu, Fei
Clinical trials referenced in this document:
Documents that mention this clinical trial
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
https://doi.org/10.1038/s41598-024-54223-5
Funding for this research was provided by:
Luye Pharma Group Ltd (LY01017/CT-CNH-101)
Article History
Received: 8 July 2023
Accepted: 9 February 2024
First Online: 13 February 2024
Competing interests
: TK, GEM, and YF are employees of Luye Pharma Group Ltd. All other authors declare no competing interests.